Latest Financial Results News

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

Boss Energy reports a strong financial foundation with positive operating cash flow and a robust balance sheet in FY2025, its first full year of uranium production. Despite a net loss driven by non-cash costs, the company positions itself for growth amid rising uranium prices.

Metal Powder Works Limited reported a 15% revenue decline and a 224% surge in net loss for FY2025, driven by acquisition costs and a pivot towards long-term contracts.

Hearts and Minds Investments (HM1) reported a stellar 25.5% pre-tax portfolio return for FY25, outperforming global benchmarks and announcing a raised fully franked dividend of 9.0 cents per share with plans for continued increases.

Virgin Australia has delivered a strong FY25 performance with pro forma underlying NPAT up 27.8%, meeting prospectus targets, while reaffirming its FY26 outlook amid operational improvements and fleet expansion.

Pathkey.AI Ltd reported a substantial reduction in its annual loss to $1.45 million for FY2025, despite a dramatic 93% plunge in revenue to just $27,783. The company’s financials reveal a cautious recovery phase with significant equity injections and a new cryptocurrency investment.

Volt Group Limited reported a 24% revenue decline and a net loss of $271,854 for the half year ended June 2025, primarily due to timing delays in Wescone orders and iron ore sector shutdowns. Despite this, the company advances its innovative ATEN waste heat to power technology and expands its EcoQuip solar light tower fleet, while initiating a 12-month on-market share buy-back.

Virgin Australia reported a 3% revenue increase and a 28% rise in underlying EBIT for FY25, while statutory net profit fell 12% due to IPO and Qatar Airways transaction costs. The airline expanded its fleet and loyalty program amid ongoing transformation efforts.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

Bapcor Limited reported a decline in FY25 pro-forma net profit after tax by 8.4%, alongside a successful $170 million debt refinancing extending maturities to 2029-2031. The company declared a fully franked final dividend and announced significant board and executive changes.

Regal Investment Fund reported a sharp 78% drop in operating profit for FY25 but maintained steady performance slightly above the RBA Cash Rate. The fund bolstered its position with a $104 million capital raise and extended its on-market buy-back program through mid-2026.

Bhagwan Marine Limited has delivered a strong first year as an ASX-listed company with record net revenue and EBITDA growth, alongside its inaugural dividend declaration. The company is advancing growth in offshore energy, subsea, ports, and defence sectors while investing in innovation and fleet expansion.